NOTCH1, SF3B1, BIRC3andTP53mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment

NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG

(2013) A. Schnaiter et al.   BLOOD

TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial

(2013) P. Dreger et al.   BLOOD

Clinical implications of the molecular genetics of chronic lymphocytic leukemia

(2013) R. Foa et al.   HAEMATOLOGICA

Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia

(2012) D. Rossi et al.   BLOOD

Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia

(2012) D. Rossi et al.   BLOOD

The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial

(2012) D. G. Oscier et al.   BLOOD

ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia

(2012) S Pospisilova et al.   LEUKEMIA

NOTCH1 mutations in CLL associated with trisomy 12

(2011) V. Balatti et al.   BLOOD

Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness

(2011) D. Rossi et al.   BLOOD

Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia

(2011) D. Rossi et al.   BLOOD

ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression

(2011) A. Guarini et al.   HAEMATOLOGICA

NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL

(2011) I. Del Giudice et al.   HAEMATOLOGICA

Mutational Status of theTP53Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial

(2011) David Gonzalez et al.   JOURNAL OF CLINICAL ONCOLOGY

Analysis of the chronic lymphocytic leukemia coding genome: role ofNOTCH1mutational activation

(2011) Giulia Fabbri et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

(2011) Xose S. Puente et al.   NATURE

Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia

(2011) Víctor Quesada et al.   NATURE GENETICS

SF3B1and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia

(2011) Lili Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL

(2010) Paolo Sportoletti et al.   BRITISH JOURNAL OF HAEMATOLOGY

White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia

(2010) I. Del Giudice et al.   HAEMATOLOGICA

TP53Mutation and Survival in Chronic Lymphocytic Leukemia

(2010) Thorsten Zenz et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness

(2009) D. Rossi et al.   CLINICAL CANCER RESEARCH

Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group

(2009) Stephan Stilgenbauer et al.   JOURNAL OF CLINICAL ONCOLOGY

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD